Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Jan 8, 2025
- Accession no.
- 0001447362-25-000006
- Filed
- Jan 8, 2025
- Trade date
- Jan 6-7, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 28 non-derivative transactions. Open-market sales total $228.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 6, 2025 | Common Stock | SSaleDisposed | −678 | $28.42F2 | −$19,268.76 | 84,084 | Direct | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −346 | $28.42F2 | −$9,833.32 | 72,755 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −325 | $28.42F2 | −$9,236.5 | 62,144 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −103 | $28.42F2 | −$2,927.26 | 5,607 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −102 | $28.42F2 | −$2,898.84 | 5,600 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −102 | $28.42F2 | −$2,898.84 | 5,600 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −102 | $28.42F2 | −$2,898.84 | 5,600 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −310 | $29.13F9 | −$9,030.3 | 83,774 | Direct | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −160 | $29.13F9 | −$4,660.8 | 72,595 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −149 | $29.13F9 | −$4,340.37 | 61,995 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −47 | $29.13F9 | −$1,369.11 | 5,560 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −47 | $29.13F9 | −$1,369.11 | 5,553 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −47 | $29.13F9 | −$1,369.11 | 5,553 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −47 | $29.13F9 | −$1,369.11 | 5,553 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −1,727 | $30.18F10 | −$52,120.86 | 82,047 | Direct | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −885 | $30.18F10 | −$26,709.3 | 71,710 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −831 | $30.18F10 | −$25,079.58 | 61,164 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −264 | $30.18F10 | −$7,967.52 | 5,296 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −262 | $30.18F10 | −$7,907.16 | 5,291 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −262 | $30.18F10 | −$7,907.16 | 5,291 | Indirect | |
| Jan 6, 2025 | Common Stock | SSaleDisposed | −262 | $30.18F10 | −$7,907.16 | 5,291 | Indirect | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −243 | $30.14F11 | −$7,324.02 | 81,804 | Direct | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −124 | $30.14F11 | −$3,737.36 | 71,586 | Indirect | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −117 | $30.14F11 | −$3,526.38 | 61,047 | Indirect | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −36 | $30.14F11 | −$1,085.04 | 5,260 | Indirect | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −37 | $30.14F11 | −$1,115.18 | 5,254 | Indirect | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −37 | $30.14F11 | −$1,115.18 | 5,254 | Indirect | |
| Jan 7, 2025 | Common Stock | SSaleDisposed | −37 | $30.14F11 | −$1,115.18 | 5,254 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $27.980 to $28.910, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $29.045 to $29.220, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F10
This transaction was executed in multiple trades at prices ranging from $30.010 to $30.380, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F11
This transaction was executed in multiple trades at prices ranging from $30.000 to $30.200, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.